Alpha Cognition (ACOG) Stock Price, News & Analysis

Company Overview

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $7.28 to $7.54
• 50-Day Range: $6.51 to $9.99
• 52-Week Range: $3.75 to $11.54
• Volume: 54,606 shs
• Average Volume: 100,805 shs
• Market Capitalization: $156.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Buy

Alpha Cognition Stock Analysis - MarketRank™

Alpha Cognition scored higher than 64% of companies evaluated by MarketBeat, and ranked 367th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Alpha Cognition has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Alpha Cognition has a consensus price target of $20.00, representing about 167.4% upside from its current price of $7.48.

Amount of Analyst Coverage

Alpha Cognition has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Cognition is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Cognition is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Cognition has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.41% of the float of Alpha Cognition has been sold short.

Short Interest Ratio / Days to Cover

Alpha Cognition has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alpha Cognition has recently decreased by 37.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Cognition does not currently pay a dividend.

Dividend Growth

Alpha Cognition does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.41% of the float of Alpha Cognition has been sold short.

Short Interest Ratio / Days to Cover

Alpha Cognition has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alpha Cognition has recently decreased by 37.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.61

News Sentiment

Alpha Cognition has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Alpha Cognition this week, compared to 1 article on an average week.

Search Interest

1 people have searched for ACOG on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Alpha Cognition to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alpha Cognition insiders have sold 96.31% more of their company's stock than they have bought. Specifically, they have bought $127,350.00 in company stock and sold $250,002.00 in company stock.

Percentage Held by Insiders

14.00% of the stock of Alpha Cognition is held by insiders. A high percentage of insider ownership can be a sign of company health.

ACOG Stock Analysis - Frequently Asked Questions

How have ACOG shares performed this year?

Alpha Cognition's stock was trading at $5.86 at the beginning of the year. Since then, ACOG shares have increased by 27.6% and is now trading at $7.48.

How were Alpha Cognition's earnings last quarter?

Alpha Cognition Inc. (NASDAQ:ACOG) issued its quarterly earnings results on Thursday, August, 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.19. The company earned $1.66 million during the quarter, compared to analyst estimates of $2.32 million.
Read the conference call transcript.

When did Alpha Cognition IPO?

Alpha Cognition (ACOG) raised $50 million in an initial public offering on Tuesday, November 12th 2024. The company issued 8,695,653 shares at a price of $5.75 per share.

How do I buy shares of Alpha Cognition?

Shares of ACOG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/05/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACOG
• CIK: 1655923
• Web: N/A
• Phone: (858) 344-4375
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alpha Cognition: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +167.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.64 million
• Net Margins: N/A
• Pretax Margin: -397.44%
• Return on Equity: -80.16%
• Return on Assets: -60.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.14
• Quick Ratio: 16.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 2.89

Miscellaneous

• Outstanding Shares: 20,900,000
• Free Float: 17,976,000
• Market Cap: $156.33 million
• Optionable: N/A
• Beta: 2.63